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inTRoducTion
The recent development of image-guided small animal 
microirradiation systems creates opportunities for radia-
tion researchers to conduct much more accurate pre-clin-
ical evaluation of novel radiotherapy techniques or 
radiotherapy-drug combinations, and to undertake exper-
iments that more reliably recapitulate clinical scenarios. 
A review of small animal radiotherapy research plat-
forms published in 2011 by Verhaegen et al1 provides a 
comprehensive overview of the systems in general use and 
outlines the key developments in irradiation, imaging and 
treatment planning that have been made possible by these 
platforms.
Meaningful pre-clinical evaluation of novel radiothera-
py-drug combinations requires thorough assessment of 
the impact of potential treatments on both the tumour 
and the relevant normal tissues [organs at risk (OARs)]. 
To maximise clinical relevance it is important that the 
relative radiation doses delivered to these structures reca-
pitulate clinical dosimetry, and that the absolute doses 
delivered can be accurately measured. Our overall research 
programme aims to improve outcomes for patients with 
glioblastoma, the most common and most aggressive 
primary brain tumour, by using novel molecular targeted 
agents to enhance tumour responses to radiotherapy 
without exacerbating adverse effects on the surrounding 
brain. The aim of this study was to evaluate four different 
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objective: Small animal radiotherapy research plat-
forms such as XStrahl’s SARRP enable more precise 
irradiation of tumours and normal tissues in pre-clin-
ical models of cancer. Using an orthotopic G7 glioblas-
toma xenograft model we studied the impact of four 
different radiotherapy plans on tumour and normal 
tissue dosimetry.
methods: Plans were created using four different 
approaches (single beam, parallel opposed pair, single 
plane arcs, couch rotation arcs) and dose volume histo-
grams (DVH) for the tumour and the relevant organs 
at risk (OARs) (mouth, ipsilateral brain, contralateral 
brain, brain stem) were compared for a sample mouse 
subject. To evaluate the accuracy of delivery, treatment 
plans were recreated in solid-water phantoms and 
delivered to radiochromic film.
Results: Favourable tumour dosimetry was achieved 
by all plans. DVH analysis showed that different plans 
could be used to spare specific OARs depending on 
the objectives of the study. The delivery accuracy of 
the various treatments was better than 2%/2mm (dose 
difference/distance to agreement) in terms of global γ 
analysis.
conclusion: Small animal radiotherapy research plat-
forms are an exciting addition to the pre-clinical 
research environment. Such systems improve the 
conformality of irradiation of tumours and OARs while 
maintaining a high degree of accuracy and enable 
investigators to optimise experiments in terms of 
tumour coverage and inclusion or exclusion of relevant 
OARs.
advances in knowledge: This study confirms the 
utility of the SARRP in terms of the accuracy of plan 
delivery, and informs decisions on treatment planning 
to optimise the clinical relevance and scientific value 
of experiments.
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radiotherapy treatment plan approaches in terms of tumour and 
OAR dosimetry.
Investigation of CD1 nude mice bearing intracranial G7 glio-
blastoma xenografts was performed on the XStrahl Small 
Animal Radiation Research Platform (SARRP, XStrahl, Ltd, 
Surrey, UK), which was originally developed at Johns Hopkins 
University.2 The ability of the SARRP to accurately deliver 
conformal radiotherapy plans was investigated by performing 
dose volume histograms (DVH) and two-dimensional film-
based analyses.
meThodS and maTeRialS
All animal experiments were performed under the relevant UK 
Home Office Project Licence and carried out with ethical approval 
from the University of Glasgow under the Animal (Scientific 
Procedures) Act 1986 and the European Union directive 2010. 
Mice were maintained in individually ventilated cages with envi-
ronmental enrichment; ARRIVE guidelines were followed.
Female CD1 nude mice were orthotopically injected with 1 × 
105 G7 primary glioblastoma cells into the subventricular zone 
as previously described.3,4 Tumours were allowed to establish for 
10–11 weeks at which time MRI was performed to confirm the 
presence and location of tumours.
The European Society for Radiotherapy and Oncology Advi-
sory Committee on Radiation Oncology Practice has recently 
published a review5 of the technologies of small animal radio-
therapy research, which gives guidance on the reporting of irra-
diations. The irradiations performed are described in accordance 
with these recommendations, which are listed in Table 2 of the 
guidelines.
Irradiations were performed using 200 kVp, 13 mA photons with 
a broad focal spot. Additional filtration of 0.5 mm copper was 
added in the beam path, giving a half-value layer of 1.0 mm of 
copper. For the 5 × 5 mm collimator used in this investigation, 
a dose-rate of approximately 150 cGy min–1 was achieved at 
isocentre for 1 cm depth in a full scatter phantom. The source to 
isocentre distance was 35 cm. All other details of irradiations are 
given elsewhere in this article.
Plan assessment
Four different approaches to irradiating a lateralised intracra-
nial tumour were investigated for their benefits and disadvan-
tages in terms of tumour coverage and OAR irradiation. The 
small size of the target volume and the mouse brain enabled us 
to consider simple beam arrangements as well as more complex, 
arc-based approaches. In terms of acute toxicity, the mouth is 
an important OAR, while ipsilateral and contralateral cerebral 
hemispheres and brainstem dosimetry are important determi-
nants of subacute and late toxicity. For experiments focusing on 
tumour growth delay and mouse survival, tumour coverage and 
mouth dosimetry are prioritised, whereas brain and brainstem 
dosimetry are critical in experiments measuring subacute and 
late toxicities.
For a single mouse subject, three-dimensional non-deformable 
registration between MRI and cone beam CT (CBCT) imaging 
was performed (Figure  1a) to enable accurate delineation of 
the cerebral hemispheres, brainstem, mouth, eyes and tumour. 
Four different plans were generated for the subject, and calcu-
lated with prescription doses altered to provide tumour coverage 
with the 95% isodose. OAR tolerances for mouse brain are not 
defined and were not utilised, as this investigation was aimed at 
providing general principles for achievable reduction of OAR 
doses. Doses were prescribed to the isocentre. Cumulative DVH 
are shown with data relative to the prescription dose, as is most 
common in clinical treatment planning.
In vivo studies of this type are generally designed using previous 
experience of the intracranial tumour model, so that irradiation 
is performed when tumours are of a certain, pre-defined size. 
It would be extremely unusual to irradiate a tumour that was 
much larger than the tumours used in this study because mice 
would become symptomatic. If a study were to be performed 
that required the larger collimator size, we would recommend 
additional evaluation of the different planning solutions. For the 
volume of tumour in this study (0.015 cm3), it was found that in 
all scenarios a 5 × 5 mm collimator provided adequate tumour 
coverage while minimising irradiation of normal tissues.
The four plans are described below and illustrated in Figure 1b–e.
Plan deliverability and accuracy
To determine the deliverability of the various treatments, and the 
geometric and dosimetric accuracy of the delivery, plans were 
delivered to Gafchromic EBT3 (Ashland Advanced Materials, 
NJ) film in solid water. The use of Gafchromic EBT3 is compre-
hensively covered in the literature.6 Dose distributions on the 
films were compared with planned doses through two-dimen-
sional γ analysis7 using MATLAB (MATLAB 2016b, The Math-
works, Natick, 2016) with the function CalcGamma (Copyright 
2015, University of Wisconsin Board of Regents) as developed by 
M. Geurts, released under the GNU GPL v. 3.0 License.8 Global 
γ analysis was calculated, with analysis performed for doses 
greater than 20% of the prescription dose.
Initially a dose response curve for the Gafchromic film was 
generated using a two-colour channel optical density-based cali-
bration, by irradiating the film to known doses. The Farmer type 
chamber (NE2571) was irradiated following the AAPM TG61 
dosimetry recommendations,9 after which the film was substi-
tuted into a similar set up where the film was positioned at the 
effective point of measurement of the chamber. The calibration 
was performed for doses between 0 and 480 cGy, and accuracy of 
the calibration curve was found to be within ±2%.
Plans of 100 cGy dose prescription at the isocentre were then 
delivered to 5 × 5 cm squares of Gafchromic film, stacked in 
the centre within four blocks of 5 × 5 × 0.5 cm of solid water 
build-up, provided with the depth-dose calibration kit from 
XStrahl. CBCT scans of the entire set up were performed upon 
which the isocentre was placed at the level of the film, segmen-
tation was performed to have all material in the field of view as 
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water and the beam geometries were created. The CBCT dose to 
the film was seen as negligible as the dose for a 360 degree CBCT 
was determined to be around 0.04 cGy in a centre of a 1 cm cube 
(designed to mimic the approximate size of a mouse head).
Image registration was performed by putting markers on the 
edges of the film that were visible on the scanned film and on 
the CBCT image. Using a rigid registration (translation and rota-
tion only) the delivered and planned doses were compared, and 
γ analysis performed over a range of dose difference and distance 
to agreement criteria to determine the accuracy of the system. 
An analysis is said to “pass” if 95% of points in the dataset have 
a γ value of less than unity. Image analysis was performed using 
absolute doses and thus proves calculation accuracy in terms of 
dose distribution and absolute dose delivery.
ReSulTS
Plan assessment
The different plan types were evaluated by exporting DVHs and 
comparing dose-volume parameters for tumour and OARs. 
Figure 2a shows there to be no appreciable difference in tumour 
coverage between the plans. When considering dose to the ipsi-
lateral brain, all arc-based plans generated a “low-dose bath” 
(Figure  2b), consistent with clinical experience using volu-
metric modulated arc treatment. This effect was also observed 
in the contralateral brain when couch rotation arc plans were 
used (Figure  2c). In contrast, static beams generated a more 
stepped dose to the ipsilateral brain, with smaller volumes 
receiving lower doses. The single field technique delivered 
higher doses (>60%) to a slightly larger volume of the ipsilat-
eral brain.
Contralateral brain dosimetry was most affected by plan type 
(Figure  2c). As anticipated, sparing of the contralateral brain 
was maximised by the single field and TopArc plans, which 
were explicitly designed for this purpose. For couch rotation arc 
plans, the shallower the gantry angle (from vertical) the better 
the sparing of the opposite cerebral hemisphere. Parallel opposed 
fields delivered high doses to the contralateral hemisphere.
The only plan types to deliver significant dose (>5%) to the 
brainstem were the Arc60 and Arc45 plans (Figure 2d), which 
delivered maximum point doses of approximately 14% of the 
prescription dose (note scale of x-axis). Tumour location and 
murine brain anatomy render it very unlikely that the brainstem 
would receive a significant dose in studies of this type.
The mouth, similarly to the brainstem, only received dose from 
plans with a large superior-inferior component of beam delivery 
(Figure  2e). The highest mouth doses (around 10–15% of 
prescription) were delivered by all of the arc-based plans (both 
single plane and couch rotation). No significant doses were deliv-
ered to the eyes (data not shown).
Rather than present Dmax the maximum dose to a 0.001 cm3 
volume is presented with the other DVH parameters as it is a 
reasonable assumption of the smallest clinically relevant volume 
irradiated.
Figure 1. Contoured colours: tumour (purple), ispilateral brain 
(light blue), contralateral brain (magenta), left eye (blue), 
right eye (green), mouth (yellow, largely out of viewing plane), 
brainstem (not shown). The lower left legends describe the 
current datasets in view in Muriplan, which can currently only 
show a background and foreground dataset, alongside con-
tours.(a) MRI-CBCT fusion for target volume delineation. (b) 
Parallel opposed pair: two opposed lateral beams positioned 
so that the central axis passes through the centre of the 
tumour. (c) Single beam – single hemisphere: a single beam 
aimed “top-down” so that the central axis passed through the 
centre of the tumour, thus sparing the contralateral cerebral 
hemisphere.(d) Single plane arcs (“TopArc”) – single hemi-
sphere: an arc that travels from gantry 40 to 0 degrees at 
couch 90, and then from 0 to 40 degrees at couch −90 to 
form an arc over the tumour from above, with the aim of spar-
ing the contralateral hemisphere of the brain while improving 
tumour conformity.(e) Couch rotation arcs (“ArcXX”): fixed 
gantry set up with a complete couch rotation designed to cre-
ate a spherical type dose distribution. Gantry angles, XX, of 
30, 45 and 60 degrees were used to modulate the sphericity 
of the distribution. In the example shown the gantry angle is 
45 degrees. CBCT, cone beam CT.
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It can be seen from Table 1 that all plans achieved both D_95% 
and V_95% values of 95% or greater, apart from the parallel 
opposed pair arrangement. Better results were generally achieved 
with more complex beam arrangements, as there were more 
options for optimisation.
Plan deliverability and accuracy
The γ criteria were tightened until pass rates dropped below 95%. 
For the single beam and parallel opposed pair cases, a single 
beam was used. The ability of the SARRP to position the gantry 
Figure 2. Tumour DVH for the six different treatment plans: (a) tumour, (b) ipsiliateral brain, (c) contralateral brain, (d) brainstem 
and (e) mouth. DVH, dose volume histograms.
Table 1. DVH parameters for the six investigated plans, in terms of the mean dose (D_mean), the maximum dose to 0.001 cm3 
(D_max_0.001 cm3), the dose to 95% of the volume (D_95%) and the volume receiving 95% of the prescription dose (V_95%)
Plan type D_mean D_max_0.001 cm3 D_95% V_95%
Parallel opposed 101.4% 105.8% 94.7% 93.8%
Single hemisphere 103.1% 107.5% 97.3% 99.2%
TopArc 101.9% 105.8% 95.1% 95.2%
Arc30 102.7% 106.3% 96.3% 98.1%
Arc45 103.2% 106.7% 96.7% 99.8%
Arc60 102.4% 106.0% 95.0% 95.0%
DVH, dose volume histograms ;
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and couch has been well-established, and local testing has found 
positioning errors to be less than 0.25 mm. For the couch rota-
tion arc type plans, only the 45 degree case was tested. The best 
γ criteria achieved for the single beam case was 2%/1.5 mm, for 
the couch arc rotation plan was 2%/0.75 mm or 1%/1.25 mm and 
for the TopArc plan was 2%/1 mm. Differences in the distance to 
agreement criteria are likely to be generated from inaccuracies 
in the image registration stage, which will be an area for future 
development. Shown in (Figure 3) are the results for the Arc 45 
couch rotation plan.
Plans were created in 20–25 min including registration of MRI 
and CBCT images, segmentation of tissue types, voluming of 
OARs and arranging beams. It is anticipated that plan creation 
times may be reduced to 15–20 min given sufficient user experi-
ence. Irradiation times were 1–2 min for simpler beam arrange-
ments, and up to 4 min for the most complex (“TopArc”) plan.
The majority of points failing were in the high-dose region of the 
beam and present as very small areas. While the film response 
and the conversion from optical density to dose will have noise 
and uncertainty contributions, no smoothing was applied to the 
measured data. As a test-case, a 10 × 10 pixel median filter was 
applied to the data and minimal gains (<0.5%) were seen in the 
pass rate for the same γ criteria. The areas where γ was failing 
were similar for all plan types.
diScuSSion
This study shows that the SARRP enables a variety of different 
radiotherapy techniques to be used in studies of orthotopic 
brain tumour models, all of which achieve excellent tumour 
coverage. Plan selection is therefore primarily dictated by the 
objectives and requirements of the study in terms of normal 
tissue dosimetry. Almost complete sparing of the contralat-
eral hemisphere can be achieved by the use of single beam 
or “TopArc” plans, of which the single beam also achieves 
maximum sparing of the mouth. For studies incorporating 
brain toxicity endpoints, arc-based techniques recapitulate 
the clinical scenario most effectively, and the Muriplan soft-
ware on the SARRP enables accurate measurement of doses 
and DVHs for OARs. There is very little data to inform OAR 
tolerances for mouse models in general and the mouse brain 
in particular. Most studies have used whole brain irradiation 
and we are not aware of any published work in this area that 
has formally evaluated different methods of focal irradiation 
of orthotopic brain tumours. Pre-clinical evaluation of radio-
therapy-drug combinations will be enhanced by accurate 
measurement of OAR dosimetry, and will facilitate accurate 
Figure 3. Couch rotation 45 arc plan results. (A) planned dose from Muriplan (cGy), (B) measured dose on Gafchromic film (cGy), 
(C) difference image, planned–measured (cGy) and (D) γ map for 1.0%/1.5 mm (no units).
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comparison of behavioural, histopathological and molecular 
sequelae of radiotherapy in the presence and absence of the 
investigational drug.
The relatively complex, arc-based treatment plans described in 
this paper were shown to be deliverable and highly accurate. 
This level of accuracy is important in the context of the small 
dimensions of both the intracranial tumours and the mouse 
brain. While excellent accuracy was generally achieved using 
the SARRP, the system in Glasgow currently requires the use 
of fixed collimators of various sizes which restricts confor-
mality to some extent. Cho et al10 have now developed a vari-
able collimator system for the SARRP which enables the user 
to more closely conform to tumour shape and size as well as to 
OAR geometry if required.
Due to machine time restrictions, repeat measurements 
could not be performed for the same plan type on different 
films, with an aim to reduce uncertainty. Gafchromic 
film, however, has been well-established as a reliable dose 
measurement method, and routine quality assurance tests 
give confidence in the reproducibility of set up and stability 
of dosimetry.
concluSionS
The ability of the SARRP to deliver accurate doses to small 
volumes is vital in providing confidence and clinical relevance 
in pre-clinical radiation studies. For relatively complex plan 
types the SARRP can deliver accurate doses while sparing OARs, 
enabling longer-term efficacy and toxicity studies.
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